Suchergebnisse - "Tiraboschi, Juan Manuel"

PubPharm (10)

1

Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir

enthalten in: The Journal of antimicrobial chemotherapy | 2023

von González-Cordón, A. | Assoumou, L. | Moyle, G. | +117

2

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk : A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023

von Waters, L. | Assoumou, L. | González-Cordón, A. | +121

3

Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV

enthalten in: AIDS (London, England) | 2022

von Donadeu, L. | Tiraboschi, J. | Scévola, S. | +13

4

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

enthalten in: The Journal of antimicrobial chemotherapy | 2021

von González-Cordón, A. | Assoumou, L. | Moyle, G. | +117

5

Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk : 48 week effects on subclinical cardiovascular disease

enthalten in: The Journal of antimicrobial chemotherapy | 2020

von Gonzalez-Cordon, A. | Assoumou, L. | Camafort, M. | +113

6

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial) : a phase 2, randomised trial

enthalten in: Lancet (London, England) | 2020

von Fidler, S. | Stöhr, W. | Pace, M. | +121

CommentIn: Lancet. 2020 Mar 14;395(10227):844-846. - PMID 32085822

7

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years : Final 96-Week Results of the NEAT022 Study

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2019

von Gatell, J. | Assoumou, L. | Moyle, G. | +124

8

Short communication : focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression

enthalten in: AIDS research and human retroviruses | 2014

von Imaz, A. | Cayuela, N. | Niubó, J. | +4

9

Consensus statement on the clinical management of human immunodeficiency virus-associated neurocognitive disorders

enthalten in: Enfermedades infecciosas y microbiologia clinica | 2014

von Grupo de expertos del Grupo de Estudio de Sida (GeSIDA) y de la Secretaría del Plan Nacional sobre el Sida (SPNS) | Podzamczer Palter, D. | Muñoz-Moreno, J. | +23

10

Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2010

von Tiraboschi, J. | Niubo, J. | Curto, J. | +1

1
[1]